Eight Questions Every Healthcare Leader Should Be Asking

The strongest strategic conversations we have with hospital leaders are not the ones in which we arrive with answers. They are the ones in which the right question changes how the conversation is framed and our collective ability to find the right answers.

The questions below have emerged from our work with NHS trusts, Irish hospitals, and US health systems, and from a recent industry session with Karen Conway, one of the most respected analysts of the global healthcare supply chain. They are not designed to be comfortable. In our experience, most executive teams cannot answer all of them with confidence today. That is precisely why they are useful as a self-assessment and for collaborative problem-solving.

They are also, taken together, a portrait of the strategic shift underway. The capabilities they describe were not, until recently, what hospital leaders expected of their supply chain function or their technology partners. They are now.

1. Can we trace any clinical product, in real time, from manufacture through to the point of care and beyond?

Traceability is no longer a procurement capability. It is a patient safety capability, a regulatory capability, and, increasingly, a clinical workflow capability. National programs such as Scan4Safety in the United Kingdom and equivalent initiatives across the Irish HSE have moved traceability from aspiration to operational expectation. The question is no longer whether an organization should be able to trace its products. It is whether the organization can do so today, and how quickly it can do so for any given item. For implanted devices in particular, traceability extends beyond the point of care to the patient record itself: in the event of a recall, the ability to link a specific device to the specific patient who received it is what turns a safety alert into a timely clinical response.

2. Do we know which clinicians use which products, in what quantities, with what clinical and financial outcomes?

Variation is where cost lives, and variation cannot be addressed without granular data. The conversation has historically focused on the high-cost implant, but variation is often greater in less visible categories: drugs, blood, oxygen, consumables. Surfacing clinician-level variation is the first step. Surfacing the clinical reason for the variation, which is sometimes a better outcome rather than a worse one, is the second step. Most organizations cannot reliably do either.

3. What proportion of our procurement contracts can we currently model for tariff, country of origin, or raw material disruption exposure?

Geopolitical volatility has moved supply chain risk from a periodic agenda item to a standing one. Country of origin intelligence and tariff exposure modeling are now expected capabilities for supply chain teams. The proportion of contracts that can be modeled this way is, for most organizations, lower than executive teams realize. Identifying that gap is the first step toward closing it.

4. If 20 percent of our surgical activity migrated to ambulatory surgery centers in the next 24 months, are our supply chain economics ready?

This question is most directly relevant to the operations of US health systems, but UK and Irish organizations should not assume it does not apply to them. Day surgery and outpatient migration are accelerating across all three markets, and the supply chain implications are substantial. Implant economics in ambulatory settings in the US are particularly unforgiving, with reimbursement structures that in some cases do not cover the cost of the implant itself. Better financial and clinical insights can help healthcare leaders make more informed decisions about the best locations for patient care.

5. How many separate systems would we have to query to assemble a complete picture of true cost for a given procedure?

The honest answer for most organizations is uncomfortable. True cost requires inputs from procurement, inventory, clinical documentation, finance, and sometimes quality. A picture assembled from five or six separate systems is a picture that takes too long to assemble to be useful, and that no one stakeholder has full confidence in. A picture assembled from a single source of truth accelerates a higher capability.

6. What is the average clinical time we save per nurse per shift through current technology, and is that measure trending in the right direction?

In the United Kingdom and Ireland, the labor hour is now the currency in which technology business cases are built. Hours of nursing time saved. Hours of clinical work returned to patient care. Hours of administrative effort eliminated. Technology that cannot translate its value into hours released to clinicians struggles to be adopted. Executive teams should know what their current baseline is, and whether it is moving. Just as important is how effectively personnel are supported to use the technology in the first place: the most common reason technology implementations underdeliver is not the tool, but the adoption.

7. Can our procurement, clinical, finance, and quality teams use the same data set to ask their own questions, or are we still operating in silos?

Centralized data science is becoming the model in major health systems for a reason. The most valuable questions in healthcare cross functional boundaries, and the right product data is often key to answering many of them. Why is the cost or utilization of this product higher than expected is the supply chain question. Is this the right product for the patient is the clinical question. How will this product impact total cost of care is the financial question. The answer requires all three teams to be looking at the same data. Most legacy supply chain technology stacks were not built to support that.

8. If a regulator asked us to demonstrate our patient safety controls on implanted devices, how quickly could we respond?

This is the question we find most consistently sharpens executive attention. Regulatory expectations on traceability and patient safety have moved faster than most organizations have prepared for. The ability to respond to a regulatory question in hours rather than weeks is a function of the underlying platform, not of how hard the team works on the day the question is asked.

A note on the questions

These questions are designed to be uncomfortable. Most executive teams cannot answer all of them with confidence today. The strategic shift across healthcare supply chain is precisely the shift that turns those question marks into operational capability.

If the questions are landing with your team, the conversation that follows them is the one worth having.